Synergistic fungicidal activity with low doses of eugenol and amphotericin B against Candida albicans

被引:25
|
作者
Khan, Shahper N. [1 ]
Khan, Shakir [1 ]
Misba, Lama [1 ]
Sharief, Muzammil [1 ]
Hashmi, Amiruddin [1 ]
Khan, Asad U. [1 ]
机构
[1] Aligarh Muslim Univ Aligarh, Interdisciplinary Biotechnol Unit, Aligarh 202002, Uttar Pradesh, India
关键词
Synergism; Antifungal activity; Reactive oxygen species (ROS); Mitochondrial hyperpolarisation; Cytochrome C; Calcium ion; OROPHARYNGEAL CANDIDIASIS; ESSENTIAL OILS; ANTIFUNGAL; EPIDEMIOLOGY; INFECTIONS; THERAPY;
D O I
10.1016/j.bbrc.2019.08.053
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Candida albicans frequently causes variety of superficial and invasive disseminated infections in HIV infected patients. Further, the emergence of non albicans species causing candidiasis predominantly in patients with advanced immune-suppression and drug resistance brings great apprehension. Hence, in this study we evaluate the capability of eugenol (EUG), a natural compound in combination with less toxic concentrations of amphotericin B (AmpB) for enhanced antifungal effects and reduced toxicity. Antifungal activity and time-kill assay were employed according to Clinical Laboratory Standard Institute (CLSI) guidelines with minor modifications on clinical isolates of Candida albicans. To confirm the synergistic interaction of EUG and AmpB, checkerboard experiments were employed. Interestingly, EUGAmp B combination shows many fold higher anti-candida activity compared to single component treatment. Furthermore, our results depicts reactive oxygen species (ROS) driven killing and mitochondria) hyperpolarisation on treatment. Our data also suggests inhibition of calcium channel by EUG and predicts longer retainment of AmpB. Pronounced cellular damage was observed with combination treatment than to EUG and AmpB alone. Our finding is helpful for the removal of toxic concentrations of antifungal agents. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:459 / 464
页数:6
相关论文
共 50 条
  • [21] Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata
    Barchiesi, F
    Spreghini, E
    Tomassetti, S
    Arzeni, D
    Giannini, D
    Scalise, G
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (12) : 4989 - 4992
  • [22] In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates
    Oz, Yasemin
    Aksit, Filiz
    Kiraz, Nuri
    Kiremitci, Abdurrahman
    MIKROBIYOLOJI BULTENI, 2008, 42 (01): : 149 - 155
  • [23] Repurposing as a means to increase the activity of amphotericin B and caspofungin against Candida albicans biofilms
    Delattin, Nicolas
    De Brucker, Katrijn
    Vandamme, Katleen
    Meert, Els
    Marchand, Arnaud
    Chaltin, Patrick
    Cammue, Bruno P. A.
    Thevissen, Karin
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (04) : 1035 - 1044
  • [24] Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model
    Zarif, L
    Graybill, JR
    Perlin, D
    Najvar, L
    Bocanegra, R
    Mannino, RJ
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (06) : 1463 - 1469
  • [25] The activity of amphotericin B against Candida albicans is not directly associated with extracellular calcium concentration
    Rogers, PD
    Kramer, RE
    Crews, JK
    Lewis, RE
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (02) : 305 - 312
  • [26] In vitro activity of amphotericin B and fluconazole in combination with atorvastatin and moxifloxacin against Candida albicans
    Kustimur, S.
    Fadil, S. J.
    Kustimur, S.
    Kalkanci, A.
    MYCOSES, 2009, 52 : 32 - 32
  • [27] Interactions between amphotericin B and nitroimidazoles against Candida albicans
    Cury, AE
    Hirschfeld, MPM
    MYCOSES, 1997, 40 (5-6) : 187 - 192
  • [28] Pharmacodynamics of fluconazole, itraconazole, and amphotericin B against Candida albicans
    Burgess, DS
    Hastings, RW
    Summers, KK
    Hardin, TC
    Rinaldi, MG
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 36 (01) : 13 - 18
  • [29] A new in-vitro kinetic model to study the pharmacodynamics of antifungal agents:: inhibition of the fungicidal activity of amphotericin B against Candida albicans by voriconazole
    Lignell, A.
    Johansson, A.
    Loewdin, E.
    Cars, O.
    Sjoelin, J.
    CLINICAL MICROBIOLOGY AND INFECTION, 2007, 13 (06) : 613 - 619
  • [30] Mode of action and synergistic effect of valinomycin and cereulide with amphotericin B against Candida albicans and Cryptococcus albidus
    Makarasen, A.
    Reukngam, N.
    Khlaychan, P.
    Chuysinuan, P.
    Isobe, M.
    Techasakul, S.
    JOURNAL DE MYCOLOGIE MEDICALE, 2018, 28 (01): : 112 - 121